Prothena

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Prothena reports robust earnings, advances Alzheimer's treatments with promising results

Prothena's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements in neurodegenerative diseases, and promising results in key programs like PRX012 and Birtamimab.
Challenges include navigating reimbursement changes, dosing complexities, and ensuring accelerated approval pathways for Alzheimer's treatments.
Opportunities lie in leveraging financial strength for pipeline expansion, upcoming data releases, innovative treatment approaches, and establishing leadership in niche disease areas.
Overall, Prothena's strategic focus on innovative therapies and deep understanding of disease mechanisms position the company for continued growth and clinical success.

Prothena reports robust financials and promising clinical advancements in Q4

Prothena's Q4 2023 earnings call highlighted strong financials, progress in key clinical programs, and promising results in movement disorder studies.
While facing challenges in patient enrollment and dose optimization, the company's focus on specialized therapies and patient-centric development positions it well for future growth.
Opportunities lie in optimizing dosing strategies, enhancing treatment efficacy, and leveraging exposure response data to drive innovation and improve therapeutic outcomes.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Prothena Corporation is a protein dysregulation specialist with a focus on developing drugs for Alzheimer's disease. The company's lead candidate, PRX012, is an amyloid clearing drug that is currently in Phase 1 clinical trials. Prothena also has other opportunities in its pipeline, including PRX005 for tau pathology and PRX123, an Aβ/tau vaccine program.

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) reports a wider-than-expected loss in the second quarter. The company makes considerable pipeline progress and updates 2023 bottom-line guidance.

Prothena (PRTA) Q2 Earnings and Revenues Miss Estimates

Prothena (PRTA) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.88 per share a year ago.

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

DUBLIN--(BUSINESS WIRE)---- $PRTA #alzheimers--Prothena today reported financial results for the second quarter and first six months of 2023 and provided business highlights.

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter 2023 financial results on August 3 after the close of the U.S. financial markets.

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena, a late-stage biotech firm, has appointed former FDA official Dr. Billy Dunn to its board and is developing therapies for neurodegenerative and rare peripheral amyloid diseases with strategic partners. The company's key candidate, Birtamimab, shows potential survival benefits for advanced-stage AL amyloidosis patients, representing a significant market opportunity. Despite recent financial losses, Prothena's strong cash position, promising pipeline, and external validation position it as a potential 'Buy' investment.

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

DUBLIN--(BUSINESS WIRE)---- $PRTA #AAIC2023--Prothena today shared data on 3 investigational product programs for the treatment and prevention of Alzheimer's disease at AAIC 2023.

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

DUBLIN--(BUSINESS WIRE)---- $PRTA #AAIC2023--Prothena today announced participation in the Alzheimer's Association International Conference® 2023 (AAIC®) being held July 16-20, 2023.

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Bristol Myers Squibb exercised its option to obtain exclusive worldwide commercial rights for PRX005.

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

DUBLIN--(BUSINESS WIRE)---- $PRTA #amyloidosis--Prothena today announced the publication of the Phase 3 VITAL clinical trial in Blood, a journal of the American Society of Hematology (ASH).

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2023 at 1:00 PM ET.

Prothena to Participate in Jefferies 2023 Healthcare Conference

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced today the appointment of Dr. Billy Dunn, the founding Director of the Office of Neuroscience, CDER, to its Board of Directors.

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Prothena's recent collaboration with Walgreens is expected to drive recruitment for Prothena's ongoing ASCENT-2 safety and tolerability trial of PRX012. PRX012, an anti-amyloid beta antibody, has shown superior binding and clearance of toxic Aβ species compared to other approved and investigational molecules in preclinical studies.

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the first quarter of 2023 and provided business highlights.

Prothena Reports First Quarter 2023 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023.

Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that members of its management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference.

Prothena to Participate in 2023 Bank of America Healthcare Conference

Walgreens

DEERFIELD, Ill. & DUBLIN--(BUSINESS WIRE)--Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena's ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer's disease.

Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer's Disease Clinical Trial

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

DUBLIN, Ireland--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .

Prothena to Participate in Stifel 2023 Virtual CNS Days

DUBLIN--(BUSINESS WIRE)---- $PRTA #ADPD2023--Prothena announced broad participation at AD/PD 2023 highlighting leadership in advancing treatments for Alzheimer's and Parkinson's disease

News for Prothena Stock (PRTA)